BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy

Completed

Conditions: Hepatitis B

First Posted Date: 2016-06-06

Last Posted Date: 2017-11-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 383

Registration Number: NCT02791386

Locations: 🇨🇳
Local Institution, Changsha, Hunan, China

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BMS-986166
Drug: Placebo matching BMS-986166

First Posted Date: 2016-06-03

Last Posted Date: 2017-11-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 66

Registration Number: NCT02790125

Locations: 🇺🇸
PPD Development, LLC, Austin, Texas, United States

Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study

Completed

Conditions: Melanoma

First Posted Date: 2016-05-23

Last Posted Date: 2022-05-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 408

Registration Number: NCT02780089

Locations: 🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸
Jefferson Medical Oncology, Philadelphia, Pennsylvania, United States
🇺🇸
Harbin Clinic, Rome, Georgia, United States

and more 59 locations

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: warfarin
Drug: dabigatran
Drug: rivaroxaban
Drug: apixaban

First Posted Date: 2016-05-11

Last Posted Date: 2016-05-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 14201

Registration Number: NCT02769078

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-986202
Drug: Placebo
Drug: Famotidine
Drug: Interferon alpha-2a recombinant
Drug: Ustekinumab

First Posted Date: 2016-05-05

Last Posted Date: 2017-08-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 357

Registration Number: NCT02763969

Locations: 🇦🇺
Local Institution, Melbourne, Australia

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Phase 2

Withdrawn

Conditions: Renal Cell Carcinoma
Melanoma
Lung Cancer

Interventions: Drug: Infliximab + Prednisone
Drug: Methylprednisolone + Prednisone

First Posted Date: 2016-05-05

Last Posted Date: 2018-10-09

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02763761

Locations: 🇺🇸
Atlantic Health System, Morristown, New Jersey, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

and more 7 locations

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: BMS-986142 200mg
Drug: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)
Drug: BMS-986142 350mg

First Posted Date: 2016-05-04

Last Posted Date: 2016-09-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28

Registration Number: NCT02762123

Locations: 🇺🇸
Ppd Development, Lp, Austin, Texas, United States

Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: ORENCIA Subcutaneous Injection

First Posted Date: 2016-05-02

Last Posted Date: 2024-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 303

Registration Number: NCT02758769

Locations: 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan
🇯🇵
Mebix, Inc., Minato-ku, Tokyo, Japan

Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela

Completed

Conditions: Non-Valvular Atrial Fibrillation

First Posted Date: 2016-04-29

Last Posted Date: 2016-04-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 80

Registration Number: NCT02756481

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Phase 1

Completed

Conditions: Malignant Solid Tumor

Interventions: Biological: BMS-986179
Biological: Nivolumab
Biological: rHuPH20

First Posted Date: 2016-04-28

Last Posted Date: 2023-04-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 235

Registration Number: NCT02754141

Locations: 🇦🇺
Local Institution - 0017, Sydney, New South Wales, Australia
🇳🇱
Local Institution - 0006, Amsterdam, Netherlands
🇺🇸
Local Institution - 0022, Boston, Massachusetts, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy